Detecting APC-resistant factor V: A functional method without plasma dilution

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6, 1999, Pages 359-366

  Rylatt, D B ^a   Hohnen Behrens, C ^a   Pilgrim, R L ^a   Dickeson, L E ^a   Neal, M ^a   Exner, Thomas ^a,b  

^a Riverside Corporate Park   (Australia)

^b Gradipore Ltd   (Australia)

Author keywords

Agkistrodon contortrix venom; APC resistance; Factor V Leiden; Heparin; Lupus anticoagulants; Protein C; Protein C pathway; Russell's viper venom; Thrombophilia testing; Warfarin

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; HEPARIN; LUPUS ANTICOAGULANT; PROTEIN C; SNAKE VENOM;

ACTIVATED PROTEIN C RESISTANCE; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CARRIER; FIBRIN FORMATION; HEMODILUTION; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOPHILIA;

EID: 0032851330     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199909000-00006     Document Type: Article

References (22)

1. 1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
2. 2. Bertina R, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 343: 1534-1538.
3. 3. Ridker PM, Hennekens CH, Lindpainter K, Stamfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
4. 4. Van der Meer FJM, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden thrombophilia study (LETS). Thromb Haemost 1997; 78: 631-635.
5. 5. De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-886.
6. 6. Zöller B, Svennson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
7. 7. Lewandowski K, Rosek M, Zawilska K, Mariewicz WT. An alternative method for identifying the factor V gene Leiden mutation. Thromb Res 1997; 85: 105-113.
8. 8. Reitsma PH, Van der Velsen PA, Vogels E, Van Strijp D, Tachen N, Adriaansen H, et al. Use of the direct RNA amplification technique NASBA to detect factor V (Leiden), a point mutation associated with APC resistance. Blood Coag Fibrinol 1996; 7: 659-663.
9. 9. Aboud MR, Ma DDF. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation. Br J Haematol 1997; 97: 798-803.
10. 10. Svensson PJ, Zoller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-335.
11. 11. Tripodi A, Negri B, Bertina R, Mannucci PM. Screening for the FV:Q506 mutation - evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-439.
12. 12. Van Oerle R, Van Pampus L, Tans G, Rosing J, Hamulyak K. The clinical application of a new functional assay to detect the factor V (Leiden) mutation associated with activated protein C resistance. Am J Clin Path 1997; 107: 521-526.
13. 13. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-1163.
14. 14. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-1190.
15. 15. Kraus M, Noah M, Fickenscher K. The PCAT - a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-222.
16. 16. Robert A, Eschwege V, Hameg H, Drouet L, Aillaud MF. Anticoagulant response to Agkistrodon Contortrix venom (ACV test): a new global test to screen for defects in the anticoagulant protein C pathway. Thromb Haemost 1996; 75: 562-566.
17. 17. Haas FJLM, van Sterkenburg-Kamp BM, Scheepers HAMM. A protein C pathway (PCP) screening test for the detection of APC resistance and protein C or S deficiencies. Semin Thromb Haemost 1998; 24: 355-362.
18. 18. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-18738.
19. 19. Gable PS, Le DT, Rapaport SI. Protac, a commercially available protein C activator from the venom of Agkistrodon contortrix contortrix, can activate factor V and factor VIII. Thromb Res 1997; 86: 79-84.
20. 20. Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306 > Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-1144.
21. 21. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg 306 of factor V in Hong Kong Chinese. Blood 1998; 91: 1135-1139.
22. 22. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.